(E) Payers should support access to GLP-1 and GLP-1/GIP RA therapy for people with T1D who are most likely to benefit (e.g., obesity/insulin resistance and elevated cardiometabolic risk), using transparent criteria that minimize inequitable barriers
Ideal candidates include adults with: BMI 30 (obesity) BMI 27 with weight-related conditions (type 2 diabetes, hypertension, high cholesterol, sleep apnea, PCOS) Inability to lose weight through diet and exercise alone Contraindications include: Personal or family history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 (MEN 2) History of pancreatitis (caution advised) Your online doctor will evaluate all risks and benefits before prescribing
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical giant
The combination of protein and fiber will help keep you full, support gastrointestinal (GI) function, and promote muscle maintenance
